About AGB-Pharma
Our vision:
Better sleep health for everyone
AGB-Pharma works to improve treatment paths for any patient living with sleep disorders and to be the healthcare sector’s primary sleep health partner.
Sleep health
AGB-Pharma is an independent, Swedish, family-owned, pharmaceutical company that focuses on sleep health and specialises in the treatment of sleep disorders.
For us, good sleep health is more than just medication. Sleep is one of our fundamental needs. Anyone who’s ever slept badly or too little – particularly for an extended period of time – knows this. But poor sleep health is rarely a simple problem – and it’s often a problem for which there is no simple solution. We are, after all, talking about the entire person, not just synapses and neurotransmitters. Good sleep health is as much a matter of practical work and experience as it is science and theory.
AGB-Pharma manufactures and markets pharmaceuticals and has its head office located in the Swedish city of Lund, where it was founded in 2020. AGB-Pharma operates in Sweden, Norway, Denmark, the UK and Germany with production facilities in Scandinavia.
AGB-Pharma hopes, through an international expansion of its treatments for sleep disorders, to increase awareness of sleep disorders and the effect they have on people who suffer them.
For us, good sleep health is more than just medication. Sleep is one of our fundamental needs. Anyone who’s ever slept badly or too little – particularly for an extended period of time – knows this. But poor sleep health is rarely a simple problem – and it’s often a problem for which there is no simple solution. We are, after all, talking about the entire person, not just synapses and neurotransmitters. Good sleep health is as much a matter of practical work and experience as it is science and theory.
AGB-Pharma manufactures and markets pharmaceuticals and has its head office located in the Swedish city of Lund, where it was founded in 2020. AGB-Pharma operates in Sweden, Norway, Denmark, the UK and Germany with production facilities in Scandinavia.
AGB-Pharma hopes, through an international expansion of its treatments for sleep disorders, to increase awareness of sleep disorders and the effect they have on people who suffer them.
Markets
EU-certified, reliable manufacturing in Scandinavia
AGB-Pharma has its manufacturing in Scandinavia and the manufacturing process is EU-certified in accordance with GMP – Good Manufacturing Practice.
Active substance and necessary excipients are kept in large stock locally and the production is scalable to ensure the demand can always be met, thereby minimising the risk of delivery problems. Our products have never been backorder listed in Sweden.1
AGB-Pharma is an independent, Swedish, family-owned, pharmaceutical company whose head office is located in the Swedish city of Lund. The company’s operations focus on sleep health and treatments for sleep disorders.
Management group – Sweden
Fredrik Lindberg, CEO
MD, PhD, Associate Professor in Clinical Pharmacology
Fredrik was appointed as the CEO of AGB-Pharma in 2020 and was tasked with building a pharmaceutical company operating in the field of sleep health from the ground up, and with launching the company’s products internationally. Before AGB-Pharma, Fredrik was the CEO of Enzymatica AB (listed on the NASDAQ First North exchange), prior to which he was the co-founder and CEO of BoneSupport AB (listed on the NASDAQ MidCap exchange). He has previously served as the Nordic Medical Director of Searle Pharmaceuticals and the Clinical Director of the Department of Clinical Pharmacology at the Skåne University Hospital in Lund.
Lars Grundemar, Chief Medical Officer
MD, PhD, Professor of Clinical Pharmacology at Lund University
Lars has extensive experience of senior roles in global pharmaceutical development and in a wide range of therapeutic areas from Pfizer (Pharmacia), Novartis, AstraZeneca and other companies in Sweden, Italy, the USA, Switzerland, and Denmark. He has also been a Board Member of several life science companies in the pharmaceutical and biotech sectors, and was the CEO of the cancer pharmaceutical company, Oncorena.
Lars is an Adjunct Professor at the University of Lund, working with experimental and clinical pharmacology and pharmaceutical development. He has particular experience of experimental and clinical R&D of pharmaceuticals in the field of neurology, psychiatry, and pain.
Magnus Pålsson Chief Commercial Officer
MBA, Heinrich-Heine-Universität Düsseldorf
Magnus has been the Chief Commercial Officer at AGB-Pharma since 2022 and was recruited from his position as the CEO of a leading, international diagnostics company in the field of women’s health.
Since graduating in Germany, Magnus has worked internationally in the life sciences sector (pharmaceuticals, health technology, and diagnostics), holding positions in both local subsidiary companies (Canada, Portugal, Sweden, and Switzerland) and global head offices (Germany, Sweden, and Finland).
Charlott Hall, Director Development and Operations
BSc in inorganic and analytical chemistry, University of Lund
Charlott took over the role of Director of Development and Operations at AGB-Pharma in 2021. The role entails responsibility for production, development, supply chain, and procurement and logistics.
Charlott has over 30 years’ experience of working in major pharmaceutical and health technology companies, including AstraZeneca, Pharmacia, Pfizer Consumer Healthcare and Gambro (subsequently Baxter.) She began her career as a laboratory engineer at AstraZeneca, since then she has worked as a research engineer, laboratory manager, and R&D Section Manager and Project Manager. Charlott has also worked in production as a Production Manager and Departmental Manager for Production Support.
Helena Eklöf, Director Regulatory, Quality Assurance and Pharmacovigilance
M.Sc. in Chemical Engineering, Faculty of Engineering (LTH), Lund University
Helena took over the role as Director of Regulatory, Quality Assurance and Pharmacovigilance in 2023 and has over 25 years’ experience of working in the pharmaceutical industry for such companies as Bioglan AB and Astra Zeneca. Helena joined AGB-Pharma from Ferring Läkemedel, where she had overall responsibility for RA, QA and PV for the Nordic marketing companies.
UK-AGB-NPR-0006 03/2024
© 2024 AGB-Pharma AB